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Genes encoding transporter
proteins comprise approxi-
mately 25% of the human
genome, which attests to the
importance of these mole-
cules in normal cellular func-
tion. Not surprisingly, cancer
cells utilize transporters,
notably members of the ATP
binding cassette (ABC) super-
family, to enhance their sur-
vival and chemoresistance.
Comprised of seven families
designated A through G, cer-
tain ABC transporters couple
the hydrolysis of ATP to move
drugs and xenobiotics unidi-
rectionally out of cells, thereby
effecting drug resistance. The
ability of ABC transporters to
efflux diverse drugs provided
an explanation for the clinical
phenomenon of multidrug
resistance, where resistance to multi-
ple agents accompanies recurrent
cancer following initial successful
treatment.
The first ABC transporter
described in association with multi-
drug resistance to chemotherapeutic
agents was ABCB1 (P-glycoprotein,
the product of the MDR1 gene),
responsible for pleiotropic resistance
to multiple classes of anticancer
agents with very different chemical
structures and mechanisms of action
(e.g. anthracyclines, Vinca alkaloids,
taxanes). The expression of ABCB1
in human tumors, particularly in acute
myelogenous leukemia (AML), and
the correlation of ABCB1 expression
with poor outcome in this disease
(Leith et al., 1999), led to trials
employing ABCB1 inhibitors in com-
bination with cytotoxic agents
effluxed by that transporter.These tri-
als, overall, proved disappointing,
suggesting that resistance mecha-
nisms in addition to or other than
ABCB1 overexpression may
be involved in clinical mul-
tidrug resistance. Hence, the
value of ABCB1 inhibition as a
therapeutic strategy is cur-
rently unsettled.
The clinical trials with
ABCB1 reversal agents and
the recognition that not all
drug-resistant cancer cells
with an ATP-dependent, drug
efflux phenotype express
ABCB1 initiated a search for
additional drug transporters.
The first of these to be dis-
covered was the multidrug
resistance protein 1 (MRP1
or ABCC1; Cole et al., 1992),
which quickly led to a search
for homologs in the human
genome, and the discovery of
other MRP family members
within the ABCC subfamily
(Borst et al., 2000). The MRP family
is represented by nine distinct mem-
bers, of which the first eight are cur-
rently associated with cancer drug
resistance in laboratory models.
MRPs overlap, in part, in their
chemotherapeutic substrate speci-
ficities with ABCB1, but broaden the
classes of agents exported to
include topoisomerase I inhibitors,
cisplatin, methotrexate, nucleosides,
nucleotides, and fluoropyrimidines.
The importance of MRP transporters
in conferring clinical drug resistance
is still undetermined.
Other ABC transporters have
been shown recently to confer mul-
tidrug resistance through transport
of clinically important antineoplastic
agents. ABCG2, or breast cancer
resistance protein (BCRP) (Doyle et
al., 1998) transports mitoxantrone,
methotrexate, topoisomerases I
inhibitors, flavopiridol, CI-1033, and,
shown most recently, imatinib mesy-
late (Burger et al., 2004). The bile
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Mining our ABCs: Pharmacogenomic approach for evaluating
transporter function in cancer drug resistance
The association of transporter proteins and cancer drug resistance has been known for approximately 25 years, with recent
discoveries pointing to an ever-increasing number of ATP binding cassette (ABC) transporter proteins involved with the
response of cancer cells to pharmacotherapy. As reported in this issue of Cancer Cell, Szakács et al. couple quantitative,
real-time PCR assays for all 48 human ABC transporters with chemosensitivity information mined from the NCI-60 cancer
cell line database. Predictions of transporter involvement in drug effect were validated in selected cases, and furthermore
produced novel leads relating ABC transporter expression and chemoresistance or chemosensitivity.
Figure 1. ABC transporters currently known or suspected
to cause resistance to cancer chemotherapeutic drugs
ABC transporters are depicted as a radial, unrooted
phylogenetic tree. To produce the figure, the protein
sequences were aligned and assembled into a phylo-
genetic tree using ClustalX 1.8 (Thompson et al., 1997),
then displayed and printed using TreeView (Win32)
1.6.6 (Page, 1996). The horizontal bar in the figure repre-
sents the relative phylogenetic distance for pairwise
alignments. Representative antineoplastic drugs known
or suspected to be subject to attenuation by these
transporters are as follows: ABCA2, estramustine; ABCB1
(P-glycoprotein or MDR1), anthracyclines, etoposide,
imatinib, taxanes, vinca alkaloids; ABCB4 (MDR2),
paclitaxel, vinblastine; ABCB11 (BSEP), paclitaxel;
ABCC1 (MRP1), anthracyclines, etoposide, methotrex-
ate, but not taxanes (a point of distinction from ABCB1
drug resistance spectrum); ABCC2 (MRP2, cMOAT), cis-
platin, doxorubicin, etoposide, methotrexate, mitox-
antrone, vinca alkaloids; ABCC3 (MRP3), cisplatin,
doxorubicin, etoposide, methotrexate, vinca alkaloids;
ABCC4 (MRP4), methotrexate, thiopurines; ABCC5
(MRP5), 6-mercaptopurine, 6-thioguanine; ABCC6
(MRP6), anthracyclines, etoposide, teniposide; ABCC10
(MRP7), docetaxel, paclitaxel, vinca alkaloids; ABCC11
(MRP8), purine and pyrimidine nucleotide analogs, NSC
671136 (reported in this issue of Cancer Cell by Szakács
et al., 2004); ABCG2 (BCRP, MXR), mitoxantrone,
methotrexate, topotecan, SN-38, imatinib, flavopiridol,
anthracyclines (if mutation present at codon 482).
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salt transporter, ABCB11 (BSEP), is
expressed at high levels in liver tissue,
and confers resistance to paclitaxel
(Childs et al., 1998). ABCA2, a trans-
porter expressed intracellularly in endo-
somal/lysosomal vesicles and involved in
steroid transport, confers resistance to
estramustine, a nitrogen mustard deriva-
tive of estradiol (Vulevic et al., 2001).
Figure 1 displays a phylogenetic tree of
the ABC family members currently impli-
cated in resistance to cancer chemother-
apeutic agents.
Of the 48 human ABC transporters,
only approximately a dozen (Figure 1) are
associated with cancer drug resistance,
and a relatively small number of known
resistance-associated transporters are
extensively characterized for substrate
specificity. Szakács and colleagues
(Szakács et al., 2004), in this issue of
Cancer Cell, have taken a pharmacoge-
nomic, hypothesis-generating approach
to expand knowledge of the specificity of
known multidrug resistance ABC trans-
porters for candidate anticancer agents,
and also to discover whether any other
ABC transporter, hitherto unknown to
cause drug resistance, can transport anti-
cancer drugs. By using real-time RT-PCR
methods to quantify the mRNA of all 48
human ABC transporters, they were able
to obtain precise correlations of data-
based drug sensitivity in a subset of 1,429
potential anticancer drugs tested on the
NCI-60 cell line panel with mRNA levels of
ABC transporters for these cells. For a
given drug-transporter pair, a negative
Pearson correlation coefficient for cell
sensitivity to drug versus transporter
expression across the 60 cell lines sug-
gests the transporter may cause drug
resistance; conversely, a positive correla-
tion coefficient would indicate the trans-
porter enhances cellular sensitivity to the
drug.
As expected, the methodology found
good agreement (negative correlations)
for known substrates of ABCB1 (P-glyco-
protein) versus ABCB1 expression, and
also predicted 18 compounds, previously
unrecognized as such, to be substrates
for ABCB1. Surprisingly, the cytotoxicity of
a number of compounds displayed a posi-
tive correlation with ABCB1 expression,
suggesting that P-glycoprotein expres-
sion may, in some cases, make drug ther-
apy more effective. For one of the
compounds with a positive correlation
coefficent (NSC 73306), this phenome-
non was validated extensively. One possi-
ble explanation for this phenomenon
might be that the expression of ABCB1
alters the growth or differentiation of the
cells in a way that makes them more sen-
sitive to the cytotoxic effects of some
drugs. For example, in Dictyostelium cells,
an ABC transporter activity defined by
rhodamine efflux blocks differentiation
and maintains cells in an undifferentiated
state by expelling a differentiation-induc-
ing factor, DIF-1, from the interior of pres-
pore cells (Good and Kuspa, 2000).
When the expression of all 48 trans-
porters was correlated with the cytotoxic-
ity data for 1,429 compounds across the
60 cell lines, the study identified 131 neg-
atively correlated transporter-drug pairs,
which included some ABC transporters
known to cause anticancer drug resis-
tance (e.g., in order of pair frequency,
ABCB1, C2, C3, B11, and C1) and some
previously unknown in this regard (e.g., in
order of frequency, ABCD1, C7, A3, and
B5). Two transporters included within
these pairs (ABCC2 and ABCC11) were
selected for further study, and the predic-
tions were found to be valid using trans-
fected cell lines, illustrating that the
method can identify novel ABC trans-
porters capable of causing drug resis-
tance. However, two ABC transporters for
which considerable evidence supports a
role in multidrug resistance—ABCC1
(MRP1) and ABCG2 (BCRP)—displayed
only weak correlation for a small number
of compounds that were not known sub-
strates for these transporters. This ambi-
guity may represent a limitation of the
new methodology for ABC transporter
screening. Perhaps for these ABC trans-
porters, there is a poor correlation
between mRNA transcript and/or protein
expression or transporter function.
Because precise quantitative mea-
surements of transcripts are required to
correlate ABC transporter expression with
databased drug sensitivity, the real-time
RT-PCR method described by Szakács et
al. (2004) offers a distinct advantage over
array-based transcriptional profiling meth-
ods, which are not sufficiently sensitive to
detect low levels of mRNA expression.
Such low levels of expression for a gene,
undetectable by microarray, could never-
theless be associated with biologically
significant activity of that gene. Hence, the
high sensitivity of the real-time PCR
approach allows precise correlations of
specific gene function and expression, as
demonstrated by Szakács et al. A limita-
tion of the real-time RT-PCR approach is
that the scope of the studies must be nar-
rowed to a relatively small number of
genes of interest. Array technology, on the
other hand, offers the ability to detect
alterations in expression of vastly more
genes than is possible or practical with
real-time PCR methods; however, the
array results may lead to more general-
ized conclusions. For example, oligonu-
cleotide microarray analysis of the NCI-60
panel revealed surprisingly good predic-
tion of cell line chemosensitivity based on
overall gene expression profiles alone
(Staunton et al., 2001), however, no spe-
cific molecular mechanism(s) of drug
resistance emerged from this study.
These global expression profiles may ulti-
mately allow prediction of resistance to a
given drug, yet considerable effort is
required to sift through the many alter-
ations observed to identify those which
are involved in the resistance process.
The work by Szakács et al. provides
evidence that this pharmacogenomic
approach is generally valid, and the num-
ber of leads selected for validation was
reasonable. Furthermore, the method pro-
vides an unbiased means to discover
novel substrates and transporters involved
with multidrug resistance compared to tra-
ditional methods, where generally a limit-
ed number of compounds are tested
against a small number of cell lines that
overexpress a given ABC transporter as
the result of drug selection or transfection.
Indeed, other leads obtained from the cur-
rent work should be pursued further, and
perhaps studies expanded to more drugs
for which sensitivity data are available in
the NCI-60 database (over 100,000
proven and/or candidate anticancer drugs
have been tested in these cell lines).
Furthermore, if combined with in vitro
cytotoxicity testing, the methodology may
ultimately lend itself to studies of clinical
samples of tumor cells, and may provide
insights as to the extent, globally, to which
ABC transporters are upregulated and
contribute to resistance to antineoplastic
therapy.
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The beginning of the 21st century has
brought the hope and expectation that an
emerging understanding of the human
genome will bring about a transformation
of the practice of medicine. In the field of
cancer, it now becomes likely that over the
next decade or two, it will become possi-
ble to classify all cancers on the basis of
their underlying genetics and physiology.
These goals are being largely addressed
through the use of DNA microarrays for
monitoring the RNA profiles of tumor
specimens. Significant progress has been
made in many areas including breast can-
cer (van de Vijver et al., 2002), lymphoma
(Rosenwald et al., 2002), and most
recently, acute myeloid leukemia (AML)
(Bullinger et al., 2004; Valk et al., 2004),
among others. A molecular taxonomy of
cancer thus appears feasible.
Yet, RNA profiles of tumor biopsies
or resected specimens cannot possibly
capture all of the relevant molecular
detail of a given cancer. For one, much of
cellular behavior is governed by transla-
tional and posttranslational control
mechanisms that are not reflected in
RNA profiles.This has led some to argue
that a definitive molecular classification
of cancer would require proteomic analy-
sis.While this may be correct in principle,
the ability to perform high-throughput,
detailed proteomic analysis of tumors is
at least several years off. As such, RNA
profiling still represents the most
tractable, high information content, high-
throughput classification platform.
Far more important than the RNA ver-
sus protein debate is the fact that molecu-
lar analysis of tumors creates a snapshot
of the biological state of the tissue at the
time of biopsy. Differences in dynamic
response to environmental conditions
(e.g., growth factor stimulation, microenvi-
ronmental effects) are not exposed. That
is, the resting profiles of two tumors could
be the same, yet their response to
provocation entirely different—and highly
relevant to understanding the clinical
behavior of human cancers.
This notion of classifying cancers
according to their dynamic response to
perturbation is explored for the first time
in an important paper by Garry Nolan and
colleagues in the July 23 issue of Cell
(Irish et al., 2004). In this work, the
authors use flow cytometry of leukemic
cells to assess the phosphorylation state
of 6 signaling proteins (Stat1, Stat3,
Stat5, Stat6, p38, and Erk1/2) in
response to 5 cytokine perturbations
(FLT3 ligand, GM-CSF, G-CSF, IL-3, and
interferon γ). The experiments were first
conducted in leukemic cell lines, and then
extended to primary blasts from patients
with AML. The studies show quite con-
vincingly that the phosphorylation status
of signaling proteins at baseline is not
predictive of their response to cytokine
stimulation. For example, Stat5, known to
be a downstream effector of the receptor
tyrosine kinase FLT3, exhibited equiva-
lent phosphorylation in FLT3 wild-type
versus mutant (resulting in constitutive
FLT3 activity) AMLs. However, Stat5
phosphorylation in response to cytokine
stimulation differed significantly between
FLT3 wild-type and mutant leukemias. In
fact, FLT3 status could be predicted
based on Stat5 (and other Stat proteins)
response to cytokine treatment. Along
those same lines, clustering of these
dynamic responses led to successful pre-
diction of response to chemotherapy.
This paper is noteworthy for several
reasons. First and foremost, it demon-
strates the feasibility of classifying tumors
(or in fact any cell) on the basis of their
response to cellular perturbation, thereby
exposing a new dimension of cellular
activity not otherwise accessible. Second,
the study demonstrates the power of
phospho-proteomic analysis, where sin-
gle cell phosphorylation status is exam-
ined. Standard flow cytometry is
reinvented as “single cell profiling” in
Toward a functional taxonomy of cancer
Interrogating the genomes of tumor cells with genomic and proteomic methods is becoming a mainstay of modern cancer
classification efforts. This notion is brought to a new level by a paper in the July 23 issue of Cell, in which the dynamic
responses of leukemia cells to perturbation are cataloged by flow cytometry, and the leukemias classified in terms of their
functional responses.This study paves the way for more systematic attempts to bring functional genomics to the study of
human cancer.
